Jeffrey Spaeder chief medical & scientific officer at Quintiles
This article was originally published in Scrip
Executive Summary
CRO Quintiles has appointed Dr Jeffrey Spaeder chief medical and scientific officer, succeeding Dr Oren Cohen who will now lead Quintiles' Phase I clinical research business. Dr Spaeder was most recently executive director of global medical affairs for Takeda Pharmaceuticals, where he worked on the strategy for the cardio-metabolic and diabetes franchises.
You may also be interested in...
Almirall launches Constella in six European markets
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira raises $35m in series B
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis ups public offering to $240m
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.